Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
Si‐Yang Maggie Liu(University of Arizona), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Chong‐Rui Xu(Guangdong Academy of Medical Sciences), Bin-Chao Wang(Guangdong Academy of Medical Sciences), Jiuwei Cui(Jilin University), Xue‐Wu Wei(Guangdong Academy of Medical Sciences), Yue‐Li Sun(Guangdong Academy of Medical Sciences), Ming-Ying Zheng(Guangdong Academy of Medical Sciences), Xiaorong Dong(The University of Melbourne), Mei-Mei Zheng(Guangdong Provincial People's Hospital), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Chang Lu(Guangdong Academy of Medical Sciences), Qing Zhou(Jiangnan University), Zhen Wang(Guangdong Academy of Medical Sciences), Jin‐Ji Yang(Guangdong General Hospital), Mingyi Yang(Guangdong Academy of Medical Sciences), Jie Huang(Sun Yat-sen University), Anna Li(Sun Yat-sen University), Xiaoyan Bai(Capital Medical University), Hua‐Jun Chen(Fujian Medical University), Yingying Du(Second Military Medical University), Bing-Fei Xu(Guangdong Academy of Medical Sciences), Jia‐Yi Deng(Kaohsiung Chang Gung Memorial Hospital), Yang-Si Li(Guangdong Academy of Medical Sciences), Qian Chu(Tongji Hospital), Hong‐Hong Yan(Sun Yat-sen University)
Cited by 11
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k